Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + cisplatin induction followed by radiotherapy with cetuximab for stage III NSCLC
2005-003867-21Phase 2Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Sahlgrenska University Hospital. Primary endpoint: Clinical benefit at 24 months. Started Nov 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-003867-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003867-21.